Literature DB >> 24940800

SUMOylation determines turnover and localization of nephrin at the plasma membrane.

Irini Tossidou1, Erik Himmelseher1, Beina Teng1, Hermann Haller1, Mario Schiffer1.   

Abstract

Podocyte effacement and the reformation of foot processes and slit diaphragms can be induced within minutes experimentally. Therefore, it seems likely that the slit diaphragm proteins underlie orchestrated recycling mechanisms under the control of posttranslational modifiers. One of these modifiers, SUMO (small ubiquitin-like modifier), is an ubiquitin-like protein with a 20% corresponding identity to ubiquitin. Modification by SUMOs to proteins on lysine residues can block the ubiquitination of the same site leading to the stabilization of the target protein. Here we found in vitro and in vivo that nephrin is a substrate modified by SUMO proteins thereby increasing its steady-state level and expression at the plasma membrane. A conversion of lysines to arginines at positions 1114 and 1224 of the intracellular tail of murine nephrin led to decreased stability of nephrin, decreased expression at the plasma membrane, and decreased PI3K/AKT signaling. Furthermore, treatment of podocytes with the SUMOylation inhibitor ginkgolic acid led to reduced membrane expression of nephrin. Similarly, the conversion of lysine to arginine at position 1100 of human nephrin caused decreased stability and expression at the plasma membrane. As SUMOylation is a reversible process, our results suggest that SUMOylation participates in the tight orchestration of nephrin turnover at the slit diaphragm.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24940800     DOI: 10.1038/ki.2014.198

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Podocyte directed therapy of nephrotic syndrome-can we bring the inside out?

Authors:  Janina Müller-Deile; Mario Schiffer
Journal:  Pediatr Nephrol       Date:  2015-05-05       Impact factor: 3.714

2.  Ehrlichia chaffeensis exploits host SUMOylation pathways to mediate effector-host interactions and promote intracellular survival.

Authors:  Paige Selvy Dunphy; Tian Luo; Jere W McBride
Journal:  Infect Immun       Date:  2014-07-21       Impact factor: 3.441

3.  A gene-expression screen identifies a non-toxic sumoylation inhibitor that mimics SUMO-less human LRH-1 in liver.

Authors:  Miyuki Suzawa; Diego A Miranda; Karmela A Ramos; Kenny K-H Ang; Emily J Faivre; Christopher G Wilson; Laura Caboni; Michelle R Arkin; Yeong-Sang Kim; Robert J Fletterick; Aaron Diaz; John S Schneekloth; Holly A Ingraham
Journal:  Elife       Date:  2015-12-11       Impact factor: 8.140

4.  CIN85 Deficiency Prevents Nephrin Endocytosis and Proteinuria in Diabetes.

Authors:  Beina Teng; Patricia Schroder; Janina Müller-Deile; Heiko Schenk; Lynne Staggs; Irini Tossidou; Ivan Dikic; Hermann Haller; Mario Schiffer
Journal:  Diabetes       Date:  2016-08-16       Impact factor: 9.461

Review 5.  Deciphering the SUMO code in the kidney.

Authors:  Zhen Yang; Yuming Zhang; Shiren Sun
Journal:  J Cell Mol Med       Date:  2018-12-01       Impact factor: 5.310

6.  Serum and Glucocorticoid-Inducible Kinase 3/Nedd4-2 Signaling Pathway Participates in Podocyte Injury by Regulating the Stability of Nephrin.

Authors:  Qing-Qing Dong; Zi-Fang Li; Hui Zhang; Hua-Pan Shu; Yu-Chi Tu; Qian-Qian Liao; Li-Jun Yao
Journal:  Front Physiol       Date:  2022-01-20       Impact factor: 4.566

Review 7.  Natural Products Against Renal Fibrosis via Modulation of SUMOylation.

Authors:  Peng Liu; Jing Zhang; Yun Wang; Chen Wang; Xinping Qiu; Dan-Qian Chen
Journal:  Front Pharmacol       Date:  2022-03-04       Impact factor: 5.810

8.  SUMO1 Promotes Mesangial Cell Proliferation Through Inhibiting Autophagy in a Cell Model of IgA Nephropathy.

Authors:  Xia Tan; Yexin Liu; Di Liu; Xiaofang Tang; Ming Xia; Guochun Chen; Liyu He; Xuejing Zhu; Hong Liu
Journal:  Front Med (Lausanne)       Date:  2022-03-31

Review 9.  Progress of small ubiquitin-related modifiers in kidney diseases.

Authors:  Ou Li; Qian Ma; Fei Li; Guang-Yan Cai; Xiang-Mei Chen; Quan Hong
Journal:  Chin Med J (Engl)       Date:  2019-02       Impact factor: 2.628

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.